Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

Liwei Lang, Chloe Shay, Yuanping Xiong, Parth Thakkar, Ron Chemmalakuzhy, Xuli Wang, Yong Teng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Methods: Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Results: Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. Conclusions: These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.

Original languageEnglish (US)
Article number85
JournalJournal of Hematology and Oncology
Volume11
Issue number1
DOIs
StatePublished - Jun 20 2018

Fingerprint

Head and Neck Neoplasms
Nanoparticles
Neoplasm Metastasis
Pharmaceutical Preparations
Nanomedicine
src-Family Kinases
Snails
Vimentin
Drug Delivery Systems
saracatinib
Carcinoma, squamous cell of head and neck
Carcinogens
Protein-Tyrosine Kinases
Wound Healing
Cell Movement
Neoplasms
Proteins
Therapeutics
Down-Regulation
Western Blotting

Keywords

  • HNSCC
  • Metastasis
  • Nanoparticles
  • Saracatinib
  • Src

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. / Lang, Liwei; Shay, Chloe; Xiong, Yuanping; Thakkar, Parth; Chemmalakuzhy, Ron; Wang, Xuli; Teng, Yong.

In: Journal of Hematology and Oncology, Vol. 11, No. 1, 85, 20.06.2018.

Research output: Contribution to journalArticle

Lang, Liwei ; Shay, Chloe ; Xiong, Yuanping ; Thakkar, Parth ; Chemmalakuzhy, Ron ; Wang, Xuli ; Teng, Yong. / Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. In: Journal of Hematology and Oncology. 2018 ; Vol. 11, No. 1.
@article{267eae3ea288465582516389f36e7493,
title = "Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib",
abstract = "Background: Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Methods: Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Results: Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. Conclusions: These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.",
keywords = "HNSCC, Metastasis, Nanoparticles, Saracatinib, Src",
author = "Liwei Lang and Chloe Shay and Yuanping Xiong and Parth Thakkar and Ron Chemmalakuzhy and Xuli Wang and Yong Teng",
year = "2018",
month = "6",
day = "20",
doi = "10.1186/s13045-018-0623-3",
language = "English (US)",
volume = "11",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib

AU - Lang, Liwei

AU - Shay, Chloe

AU - Xiong, Yuanping

AU - Thakkar, Parth

AU - Chemmalakuzhy, Ron

AU - Wang, Xuli

AU - Teng, Yong

PY - 2018/6/20

Y1 - 2018/6/20

N2 - Background: Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Methods: Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Results: Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. Conclusions: These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.

AB - Background: Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter in tumor progression and metastasis of HNSCC. However, Src therapy for HNSCC is limited by lack of efficient in vivo delivery and underlying mechanisms remain elusive. Methods: Src knockdown cells were achieved by lentiviral-mediated interference. Cell migration and invasion were examined by wound healing and Transwell assays. Protein levels were determined by Western blot and/or immunohistochemistry. The Src inhibitor saracatinib was loaded into self-assembling nanoparticles by the solvent evaporation method. An experimental metastasis mouse model was generated to investigate the drug efficacy in metastasis. Results: Blockade of Src kinase activity by saracatinib effectively suppressed invasion and metastasis of HNSCC. Mechanistic assessment of the drug effects in HNSCC cells showed that saracatinib induced suppression of Src-dependent invasion/metastasis through downregulating the expression levels of Vimentin and Snail proteins. In tests in mice, saracatinib loaded into the novel multifunctional nanoparticles exhibited superior effects on suppression of HNSCC metastasis compared with the free drug, which is mainly attributed to highly specific and efficient tumor-targeted drug delivery system. Conclusions: These findings and advances are of great importance to the development of Src-targeted nanomedicine as a more effective therapy for metastatic HNSCC.

KW - HNSCC

KW - Metastasis

KW - Nanoparticles

KW - Saracatinib

KW - Src

UR - http://www.scopus.com/inward/record.url?scp=85048755388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048755388&partnerID=8YFLogxK

U2 - 10.1186/s13045-018-0623-3

DO - 10.1186/s13045-018-0623-3

M3 - Article

VL - 11

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 85

ER -